C₂₂₁H₃₄₂N₄₆O₆₈ · 4,731.33 g/mol
Retatrutide (LY3437943)
Retatrutide is a 39-amino acid synthetic peptide engineered from a GIP backbone that acts as a triple agonist at GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it represents a new class of multi-receptor agonist peptides. Phase 2 trial data published in the New England Journal of Medicine demonstrated significant effects on body weight and metabolic markers. Phase 3 trials in 2026 (TRIUMPH-1) are expected to report 80-week obesity data. The C20 fatty diacid moiety at position 17 enables once-weekly dosing in research protocols.
Research Areas
- •Obesity research
- •Triple-receptor agonism
- •GLP-1 pathway
- •Metabolic syndrome
- •Weight management
Molecular Specifications
Molecular Formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight
4,731.33 g/mol
Purity
≥98.0%
Select Size
Prices are subject to change. Final pricing will be confirmed at checkout.
Certificates of Analysis
Current batch test results for Retatrutide (LY3437943). Click any row to download the full lab report PDF — third-party HPLC, USP<85> endotoxin, and USP<71> microbial testing.
You May Also Like
AOD-9604
Modified growth hormone fragment for metabolic and fat metabolism research.
From $64.99
View DetailsSemaglutide
GLP-1 receptor agonist — the most-studied incretin mimetic in clinical research.
From $77.99
View DetailsTirzepatide
Dual GIP/GLP-1 receptor agonist — next-generation incretin research peptide.
From $142.99
View Details